Strategic Move Bolsters Production and Financial Strength for 2026 What does the future hold for energy companies in a volatile market? Vitesse Energy, Inc. a leading non-operator in oil and gas wells, has announced a strategic all-stock acquisition of non-operated…
Mike Fedock, Executive Vice President and CFO of IQVIA, will present at the upcoming Barclays Global Healthcare Conference, highlighting the company’s strategic and financial outlook. IQVIA Holdings Inc, a global leader in clinical research services, advanced analytics, and healthcare intelligence,…
Meiji Seika Pharma’s Morcamilast (ME3183) Receives Orphan Medicinal Product Designation from the European Commission for Palmoplantar Pustulosis Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo; President and Representative Director: Toshiaki Nagasato) has announced a significant milestone in the development of its…
Autobahn Therapeutics, a clinical-stage biotechnology company advancing restorative therapies for individuals living with neuropsychiatric and neuroimmunologic disorders, today announced the presentation of new preclinical data supporting its lead investigational compound, elunetirom, at the 64th Annual American College of Neuropsychopharmacology Annual…
Axelspace Corporation, a Japanese microsatellite developer and operator guided by its mission of “Space at Your Fingertips,” has entered into a memorandum of understanding (MoU) with Jethi Software Development PLC, an Ethiopian technology firm, to collaborate on addressing pressing social…
Agenus Inc. , a leader in immuno-oncology innovation, announced the completion of its previously disclosed strategic collaboration with Zydus Lifesciences Ltd., a transaction designed to accelerate the global development and potential commercialization of Agenus’ botensilimab and balstilimab (BOT+BAL) combination immunotherapy…
Almirall, a global pharmaceutical company focused exclusively on medical dermatology, has announced plans to initiate a Phase III clinical study evaluating the efficacy and safety of lebrikizumab in adult patients with nummular eczema. The study, named LumiNE, is scheduled to…
Integrated DNA Technologies Expands Synthetic Biology Portfolio Through Strategic Collaboration with Ansa Biotechnologies Integrated DNA Technologies (IDT), a Danaher company and a global leader in genomics, has announced a strategic collaboration with Ansa Biotechnologies, Inc., a pioneering company in DNA…
BridgeBio Pharma, Inc., a biopharmaceutical company focused on developing treatments for genetic diseases, announced plans to advance its long-term balance sheet strategy through a significant new financing initiative. The company disclosed that it intends to offer $550 million in aggregate…
Celltrion delivered a comprehensive update on its long-term growth strategy and next-generation therapeutic portfolio during the 44th Annual J.P. Morgan Healthcare Conference held in San Francisco, California. The global biopharmaceutical leader outlined major advances across its innovative drug pipeline—including antibody-drug…